Mary Waterhouse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mary Waterhouse has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Rachel E. Neale
Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
12 shared publications - David C. Whiteman
QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
7 shared publications - Gunter Hartel
QIMR Berghofer Medical Research Institute
5 shared publications - Hai Pham
Queensland Digital Health Centre, Faculty of Health, Medicine and Behavioural Sciences University of Queensland Brisbane Queensland Australia
5 shared publications - Alison Venn
Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia (T.D., A.J.V.).
4 shared publications - Bruce K. Armstrong
School of Public Health, University of Sydney, Sydney, Australia
4 shared publications
Latest Publications
- Open Access
Effect of Vitamin D Supplementation on Cardiometabolic Outcomes in Older Australian Adults—Results from the Randomized Controlled D-Health Trial
Background/Objectives: Observational studies have found inverse associations between 25-hydroxyvitamin D concentration and risk of hypertension, hypercholesterolemia and type 2 diabetes (T2D). More robust evidence from large-scale randomized controlled trials, however, is limited or inconclusive. Methods: The D-Health Trial (N = 21,315) is a randomized, double-blind, placebo-controlled trial of supplementation with monthly doses of 60,000 international units of oral vitamin D3, conducted in Australians aged 60–84 years. Commencing treatment with anti-hypertensive, lipid-modifying, or anti-diabetic drugs was used as a surrogate for incident hypertension, hypercholesterolemia, and T2D, respectively. Outcomes were ascertained via linkage with the Australian Pharmaceutical Benefits Scheme database. Follow-up began 6 months after randomization; we excluded participants without linked data, and those who were prevalent cases or who died prior to start of follow-up. Flexible parametric survival models were used to estimate the effect of vitamin D supplementation on each outcome. Results: We included 10,964 participants (vitamin D, n = 5456 [49.8%]; placebo, n = 5508 [50.2%]) in the analysis of hypertension, 12,126 participants (vitamin D, n = 6038 [49.8%]; placebo, n = 6088 [50.2%]) in the analysis of hypercholesterolemia, and 17,846 (vitamin D, n = 8931 [50.0%]; placebo, n = 8915 [50.0%]) in the analysis of T2D. Over a median follow-up of 4.6 years, 2672 (24.4%), 2554 (21.1%), and 779 (4.4%) participants developed hypertension, hypercholesterolemia, and T2D, respectively. Vitamin D supplementation had no material effect on the incidence of any of hypertension (HR 1.00; 95% CI 0.93 to 1.08), hypercholesterolemia (HR 1.05; 95% CI 0.97 to 1.13), or T2D (HR 0.97; 95% CI 0.84 to 1.12). Conclusions: Monthly supplements of vitamin D did not alter the incidence of any of the three conditions in older, largely vitamin D-replete Australians.
Open AccessEffect of Vitamin D Supplementation on Cardiometabolic Outcomes in Older Australian Adults—Results from the Randomized Controlled D-Health Trial
Background/Objectives: Observational studies have found inverse associations between 25-hydroxyvitamin D concentration and risk of hypertension, hypercholesterolemia and type 2 diabetes (T2D). More robust evidence from large-scale randomized controlled trials, however, is limited or inconclusive. Methods: The D-Health Trial (N = 21,315) is a randomized, double-blind, placebo-controlled trial of supplementation with monthly doses of 60,000 international units of oral vitamin D3, conducted in Australians aged 60–84 years. Commencing treatment with anti-hypertensive, lipid-modifying, or anti-diabetic drugs was used as a surrogate for incident hypertension, hypercholesterolemia, and T2D, respectively. Outcomes were ascertained via linkage with the Australian Pharmaceutical Benefits Scheme database. Follow-up began 6 months after randomization; we excluded participants without linked data, and those who were prevalent cases or who died prior to start of follow-up. Flexible parametric survival models were used to estimate the effect of vitamin D supplementation on each outcome. Results: We included 10,964 participants (vitamin D, n = 5456 [49.8%]; placebo, n = 5508 [50.2%]) in the analysis of hypertension, 12,126 participants (vitamin D, n = 6038 [49.8%]; placebo, n = 6088 [50.2%]) in the analysis of hypercholesterolemia, and 17,846 (vitamin D, n = 8931 [50.0%]; placebo, n = 8915 [50.0%]) in the analysis of T2D. Over a median follow-up of 4.6 years, 2672 (24.4%), 2554 (21.1%), and 779 (4.4%) participants developed hypertension, hypercholesterolemia, and T2D, respectively. Vitamin D supplementation had no material effect on the incidence of any of hypertension (HR 1.00; 95% CI 0.93 to 1.08), hypercholesterolemia (HR 1.05; 95% CI 0.97 to 1.13), or T2D (HR 0.97; 95% CI 0.84 to 1.12). Conclusions: Monthly supplements of vitamin D did not alter the incidence of any of the three conditions in older, largely vitamin D-replete Australians.
- Open Access
- 6 January 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (765) , e319-e328
Decision support tools for pancreatic cancer detection: external validation in Australian primary care — a retrospective cohort study
Background: Pancreatic cancer is often diagnosed at an advanced stage with poor survival. Risk assessment tools have been developed to aid early diagnosis of pancreatic cancer in primary care settings (QCancer ® , electronic Risk Assessment Tool [eRAT], and the Queensland Institute of Medical Research [QIMR] Berghofer Pancreatic Cancer Decision Support Tool [QPaC Tool]) but have not been validated in the Australian setting. Aim: To estimate and compare the performance of these tools for identifying patients with undiagnosed pancreatic cancer using Australian primary care data. Design and setting: A cohort study was conducted using linked primary care and cancer registry data from Victoria, Australia. Method: Patients presenting to primary care with signs and/or symptoms included in the tools (recorded in the primary care ‘reason for encounter’) were included. Diagnostic accuracy statistics for each tool (and their individual signs and symptoms) were compared. Results: Patients with pancreatic cancer were more likely ( P ® was 0.8% (95% CI = 0.54 to 1.15). Conclusion: When applied to Australian primary care data, none of the tools were strongly predictive of pancreatic cancer. New diagnostic models incorporating additional data could potentially improve their predictive performance.
- 6 January 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (765) , e319-e328
Open AccessDecision support tools for pancreatic cancer detection: external validation in Australian primary care — a retrospective cohort study
Background: Pancreatic cancer is often diagnosed at an advanced stage with poor survival. Risk assessment tools have been developed to aid early diagnosis of pancreatic cancer in primary care settings (QCancer ® , electronic Risk Assessment Tool [eRAT], and the Queensland Institute of Medical Research [QIMR] Berghofer Pancreatic Cancer Decision Support Tool [QPaC Tool]) but have not been validated in the Australian setting. Aim: To estimate and compare the performance of these tools for identifying patients with undiagnosed pancreatic cancer using Australian primary care data. Design and setting: A cohort study was conducted using linked primary care and cancer registry data from Victoria, Australia. Method: Patients presenting to primary care with signs and/or symptoms included in the tools (recorded in the primary care ‘reason for encounter’) were included. Diagnostic accuracy statistics for each tool (and their individual signs and symptoms) were compared. Results: Patients with pancreatic cancer were more likely ( P ® was 0.8% (95% CI = 0.54 to 1.15). Conclusion: When applied to Australian primary care data, none of the tools were strongly predictive of pancreatic cancer. New diagnostic models incorporating additional data could potentially improve their predictive performance.
- Open Access
- 14 November 2025
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 10 (3)
The sensitivity of decision support tools for identifying patients with pancreatic cancer: an observational study
Background: Pancreatic cancer causes non-specific symptoms, potentially leading to delays in diagnosis. Decision support tools may help primary care practitioners to triage patients for pancreatic imaging. Aim: To investigate the sensitivity of three different tools for identifying patients who may have pancreatic cancer. Design & setting: An observational study in Australia. Method: We investigated the performance of the Risk Assessment Tool (RAT) for pancreatic cancer, the QCancer ® tool, and a tool developed through a consensus process led by QIMR Berghofer (the QPaC Tool). We applied these tools to people with pancreatic cancer who were interviewed about their symptoms on first presentation to a clinician. We designated patients as ‘flagged’ by each tool if they met specific criteria, and calculated the percentage flagged (that is, the sensitivity). Participants with jaundice were excluded from analyses of QCancer ® . Results: We included 190 participants in analyses of the RAT and QPaC Tool (142 in analyses of QCancer ® ). The sensitivity of the QPaC Tool and the RAT were 54% and 27%, respectively. QCancer ® had a sensitivity of 14%, at a probability threshold of 1%; in the same 142 participants, QPaC and the RAT flagged 44% and 7%, respectively. Conclusion: The QPaC Tool was the most sensitive, largely owing to its inclusion of severe epigastric pain and emphasis on diabetes, but it has unknown specificity. More research is needed to determine whether any tool could reduce delays in diagnosis; in the interim, the QPaC Tool may support clinicians to consider pancreatic cancer in their differential diagnoses.
- 14 November 2025
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 10 (3)
Open AccessThe sensitivity of decision support tools for identifying patients with pancreatic cancer: an observational study
Background: Pancreatic cancer causes non-specific symptoms, potentially leading to delays in diagnosis. Decision support tools may help primary care practitioners to triage patients for pancreatic imaging. Aim: To investigate the sensitivity of three different tools for identifying patients who may have pancreatic cancer. Design & setting: An observational study in Australia. Method: We investigated the performance of the Risk Assessment Tool (RAT) for pancreatic cancer, the QCancer ® tool, and a tool developed through a consensus process led by QIMR Berghofer (the QPaC Tool). We applied these tools to people with pancreatic cancer who were interviewed about their symptoms on first presentation to a clinician. We designated patients as ‘flagged’ by each tool if they met specific criteria, and calculated the percentage flagged (that is, the sensitivity). Participants with jaundice were excluded from analyses of QCancer ® . Results: We included 190 participants in analyses of the RAT and QPaC Tool (142 in analyses of QCancer ® ). The sensitivity of the QPaC Tool and the RAT were 54% and 27%, respectively. QCancer ® had a sensitivity of 14%, at a probability threshold of 1%; in the same 142 participants, QPaC and the RAT flagged 44% and 7%, respectively. Conclusion: The QPaC Tool was the most sensitive, largely owing to its inclusion of severe epigastric pain and emphasis on diabetes, but it has unknown specificity. More research is needed to determine whether any tool could reduce delays in diagnosis; in the interim, the QPaC Tool may support clinicians to consider pancreatic cancer in their differential diagnoses.
- 10 September 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (6) , 1128-1137
Effect of daily sunscreen application on vitamin D: findings from the open-label randomized controlled Sun-D Trial
Background: Sunscreen reduces vitamin D production in experimental studies. It is uncertain whether this translates to real-world settings. Objectives: To determine if routinely applying high sun protection factor (SPF) sunscreen for a year reduces serum 25-hydroxyvitamin D [25(OH)D] concentration. Methods: We conducted a population-based open-label randomized controlled trial in Australian participants aged 18–70 years who were not routinely using sunscreen or taking vitamin D supplements. Participants were randomized (1 : 1) using stratified, computer-generated permuted block randomization to routine application of SPF 50+ sunscreen on days the ultraviolet (UV) index was forecast to reach ≥ 3 (intervention) or discretionary sunscreen use (control), for approximately 1 year. We measured 25(OH)D concentration at baseline (winter/spring 2022) and at the end of summer and winter 2023; participants with no postbaseline concentrations (n = 11) were excluded from analyses. The primary outcome was change in 25(OH)D concentration from baseline. Vitamin D deficiency [25(OH)D concentration < 50 nmol L–1] in the final sample was an exploratory outcome. We analysed data using mixed-effects models and Poisson regression. We stratified our analysis by baseline 25(OH)D concentration, residential UV radiation (UVR) zone, skin exposure (derived from time outdoors and clothing use) and personal UVR exposure (derived by combining UVR zone and skin exposure). Sample and data analysis were performed blind to randomization group. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621001752853). Results: Between 30 June and 29 November 2022, we randomized 639 participants (intervention, n = 319; control, n = 320). In total, 628 participants were analysed [intervention, n = 312; control, n = 316; median age 52 years (interquartile range 40–64)]. Altogether, 415 (66.1%) identified as female, 210 (33.4%) as male and 3 (0.5%) used another term. Mean (SD) baseline 25(OH)D concentration was balanced [intervention 63.5 (21.9) nmol L–1; control 62.1 (22.8) nmol L–1]. Adjusted mean differences from baseline were 1.6 nmol L–1 (intervention) and 6.8 nmol L–1 (control) [between-group treatment effect –5.2 nmol L–1, 95% confidence interval (CI) –7.2 to –3.2]. Treatment effects were consistent across almost all subgroups. Vitamin D deficiency (final sample) was higher in the intervention (n = 139/304; 45.7%) than in the control group (n = 115/312; 36.9%) (prevalence ratio 1.33, 95% CI 1.14–1.55). Conclusions: Routinely applying high SPF sunscreen results in lower 25(OH)D concentrations than would be seen with discretionary sunscreen use. Regular sunscreen users may need vitamin D supplementation.
- 10 September 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (6) , 1128-1137
Effect of daily sunscreen application on vitamin D: findings from the open-label randomized controlled Sun-D Trial
Background: Sunscreen reduces vitamin D production in experimental studies. It is uncertain whether this translates to real-world settings. Objectives: To determine if routinely applying high sun protection factor (SPF) sunscreen for a year reduces serum 25-hydroxyvitamin D [25(OH)D] concentration. Methods: We conducted a population-based open-label randomized controlled trial in Australian participants aged 18–70 years who were not routinely using sunscreen or taking vitamin D supplements. Participants were randomized (1 : 1) using stratified, computer-generated permuted block randomization to routine application of SPF 50+ sunscreen on days the ultraviolet (UV) index was forecast to reach ≥ 3 (intervention) or discretionary sunscreen use (control), for approximately 1 year. We measured 25(OH)D concentration at baseline (winter/spring 2022) and at the end of summer and winter 2023; participants with no postbaseline concentrations (n = 11) were excluded from analyses. The primary outcome was change in 25(OH)D concentration from baseline. Vitamin D deficiency [25(OH)D concentration < 50 nmol L–1] in the final sample was an exploratory outcome. We analysed data using mixed-effects models and Poisson regression. We stratified our analysis by baseline 25(OH)D concentration, residential UV radiation (UVR) zone, skin exposure (derived from time outdoors and clothing use) and personal UVR exposure (derived by combining UVR zone and skin exposure). Sample and data analysis were performed blind to randomization group. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621001752853). Results: Between 30 June and 29 November 2022, we randomized 639 participants (intervention, n = 319; control, n = 320). In total, 628 participants were analysed [intervention, n = 312; control, n = 316; median age 52 years (interquartile range 40–64)]. Altogether, 415 (66.1%) identified as female, 210 (33.4%) as male and 3 (0.5%) used another term. Mean (SD) baseline 25(OH)D concentration was balanced [intervention 63.5 (21.9) nmol L–1; control 62.1 (22.8) nmol L–1]. Adjusted mean differences from baseline were 1.6 nmol L–1 (intervention) and 6.8 nmol L–1 (control) [between-group treatment effect –5.2 nmol L–1, 95% confidence interval (CI) –7.2 to –3.2]. Treatment effects were consistent across almost all subgroups. Vitamin D deficiency (final sample) was higher in the intervention (n = 139/304; 45.7%) than in the control group (n = 115/312; 36.9%) (prevalence ratio 1.33, 95% CI 1.14–1.55). Conclusions: Routinely applying high SPF sunscreen results in lower 25(OH)D concentrations than would be seen with discretionary sunscreen use. Regular sunscreen users may need vitamin D supplementation.
- Open Access
Factors Associated with Vitamin D Testing: A Population-Based Cohort Study in Queensland, Australia
Background/Objectives: Vitamin D testing has increased significantly in developed countries in recent decades. We aimed to describe trends in vitamin D testing rates and factors associated with testing and vitamin D deficiency in Queensland, Australia (2011–2019). Methods: We used data from the QSkin Sun and Health Study (n = 40,417), a prospective population-based cohort study with linkage to the Medicare Benefits Schedule, Pharmaceutical Benefits Scheme, and pathology laboratories. Main outcomes included age-standardized incidence rate of vitamin D testing; having ≥1 vitamin D test during follow-up; vitamin D deficiency (25-hydroxyvitamin D concentration <50 nmol/L) in the first vitamin D test; and repeat vitamin D tests. Results: The age-standardized incidence rate of testing increased by 2% per quarter during follow-up. Of the 35,250 participants analyzed for associations with testing (median age of 57 years, 52% female), 45% had ≥1 vitamin D test. Among those tested, 56% had no apparent clinical indication for their initial vitamin D test, 21% were vitamin D deficient in their initial test, and 58% had a repeat test. Repeat testing occurred in 56% who were not deficient in their prior test, while only two-thirds of those deficient received a follow-up assessment. Participants who visited a general practitioner ≥2 times in the year prior to follow-up were 60% more likely to have ≥1 vitamin D test compared with those with no visit, but general practitioner (GP) visits were not associated with risk of vitamin D deficiency. Conclusions: These results suggest that initiatives are needed to help clinicians target vitamin D testing in alignment with clinical guidelines.
Open AccessFactors Associated with Vitamin D Testing: A Population-Based Cohort Study in Queensland, Australia
Background/Objectives: Vitamin D testing has increased significantly in developed countries in recent decades. We aimed to describe trends in vitamin D testing rates and factors associated with testing and vitamin D deficiency in Queensland, Australia (2011–2019). Methods: We used data from the QSkin Sun and Health Study (n = 40,417), a prospective population-based cohort study with linkage to the Medicare Benefits Schedule, Pharmaceutical Benefits Scheme, and pathology laboratories. Main outcomes included age-standardized incidence rate of vitamin D testing; having ≥1 vitamin D test during follow-up; vitamin D deficiency (25-hydroxyvitamin D concentration <50 nmol/L) in the first vitamin D test; and repeat vitamin D tests. Results: The age-standardized incidence rate of testing increased by 2% per quarter during follow-up. Of the 35,250 participants analyzed for associations with testing (median age of 57 years, 52% female), 45% had ≥1 vitamin D test. Among those tested, 56% had no apparent clinical indication for their initial vitamin D test, 21% were vitamin D deficient in their initial test, and 58% had a repeat test. Repeat testing occurred in 56% who were not deficient in their prior test, while only two-thirds of those deficient received a follow-up assessment. Participants who visited a general practitioner ≥2 times in the year prior to follow-up were 60% more likely to have ≥1 vitamin D test compared with those with no visit, but general practitioner (GP) visits were not associated with risk of vitamin D deficiency. Conclusions: These results suggest that initiatives are needed to help clinicians target vitamin D testing in alignment with clinical guidelines.
- 1 November 2023
- Published by SAGE Publications in Thyroid®
- Vol. 33 (11) , 1302-1310
The Effect of Vitamin D Supplementation on Hypothyroidism in the Randomized Controlled D-Health Trial
Background: Hypothyroidism is common, and in iodine-sufficient areas is primarily caused by autoimmune destruction of the thyroid gland. Observational studies have consistently shown an inverse association between serum 25-hydroxyvitamin D concentration and autoimmune diseases; however, there is a lack of evidence from randomized controlled trials to support a benefit of vitamin D supplementation, particularly for autoimmune thyroid diseases. We therefore aimed to assess the effect of vitamin D supplementation on the incidence of hypothyroidism. Methods: We analyzed data from the D-Health Trial (N=21,315), a randomized, double-blind, placebo-controlled trial of 60,000 international units per month of supplemental vitamin D3 among Australians aged 60 years and over. Hypothyroidism, a tertiary outcome of the D-Health Trial, was defined by treatment with levothyroxine, ascertained via linkage with the Australian Pharmaceutical Benefits Scheme. The outcome was time to first prescription of levothyroxine. We began follow-up at 12 months after randomization; people who had died or who had been dispensed levothyroxine during the first year were excluded. Flexible parametric survival models were used to assess the effect of vitamin D supplementation on hypothyroidism, overall and within strata defined by age, sex, body mass index, and predicted baseline vitamin D status. Results: We included 17,851 participants in the main analysis (vitamin D=8939; placebo=8912). During a median follow up of 4.1 years (IQR 4.1–4.1) 293 participants developed hypothyroidism (vitamin D=138 [1.5%]; placebo=155 [1.7%]). Vitamin D supplementation did not significantly reduce the incidence of hypothyroidism (overall hazard ratio [HR] 0.89; 95% confidence interval [CI] 0.71–1.12). There was some suggestion of an effect in females (overall HR 0.78; 95% CI 0.58–1.06) but not in males (overall HR 1.06; 95% CI 0.74–1.50; p interaction 0.20). Conclusions: Vitamin D supplementation did not reduce the incidence of hypothyroidism overall; however, the possible beneficial effect observed in females warrants further investigation. Clinical Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000743763.
- 1 November 2023
- Published by SAGE Publications in Thyroid®
- Vol. 33 (11) , 1302-1310
The Effect of Vitamin D Supplementation on Hypothyroidism in the Randomized Controlled D-Health Trial
Background: Hypothyroidism is common, and in iodine-sufficient areas is primarily caused by autoimmune destruction of the thyroid gland. Observational studies have consistently shown an inverse association between serum 25-hydroxyvitamin D concentration and autoimmune diseases; however, there is a lack of evidence from randomized controlled trials to support a benefit of vitamin D supplementation, particularly for autoimmune thyroid diseases. We therefore aimed to assess the effect of vitamin D supplementation on the incidence of hypothyroidism. Methods: We analyzed data from the D-Health Trial (N=21,315), a randomized, double-blind, placebo-controlled trial of 60,000 international units per month of supplemental vitamin D3 among Australians aged 60 years and over. Hypothyroidism, a tertiary outcome of the D-Health Trial, was defined by treatment with levothyroxine, ascertained via linkage with the Australian Pharmaceutical Benefits Scheme. The outcome was time to first prescription of levothyroxine. We began follow-up at 12 months after randomization; people who had died or who had been dispensed levothyroxine during the first year were excluded. Flexible parametric survival models were used to assess the effect of vitamin D supplementation on hypothyroidism, overall and within strata defined by age, sex, body mass index, and predicted baseline vitamin D status. Results: We included 17,851 participants in the main analysis (vitamin D=8939; placebo=8912). During a median follow up of 4.1 years (IQR 4.1–4.1) 293 participants developed hypothyroidism (vitamin D=138 [1.5%]; placebo=155 [1.7%]). Vitamin D supplementation did not significantly reduce the incidence of hypothyroidism (overall hazard ratio [HR] 0.89; 95% confidence interval [CI] 0.71–1.12). There was some suggestion of an effect in females (overall HR 0.78; 95% CI 0.58–1.06) but not in males (overall HR 1.06; 95% CI 0.74–1.50; p interaction 0.20). Conclusions: Vitamin D supplementation did not reduce the incidence of hypothyroidism overall; however, the possible beneficial effect observed in females warrants further investigation. Clinical Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000743763.
- Open Access
- 18 February 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (2) , 2465-2481
Vitamin D and Sun Exposure: A Community Survey in Australia
Sun exposure carries both harms and benefits. Exposing the skin to the sun is the main modifiable cause of skin cancers, which exert a considerable health and economic burden in Australia. The most well-established benefit of exposure to ultraviolet (UV) radiation is vitamin D production. Australia has the highest incidence of skin cancer in the world but, despite the high ambient UV radiation, approximately one quarter of the population is estimated to be vitamin D deficient. Balancing the risks and benefits is challenging and requires effective communication. We sought to provide a snapshot of public knowledge and attitudes regarding sun exposure and vitamin D and to examine the associations between these factors and sun protective behaviors. In 2020 we administered an online survey; 4824 participants with self-reported fair or medium skin color were included in this analysis. Only 25% and 34% of participants were able to identify the amount of time outdoors needed to maintain adequate vitamin D status in summer and winter, respectively and 25% were concerned that sunscreen use inhibits vitamin D synthesis. This lack of knowledge was associated with suboptimal sun protection practices. Public education is warranted to prevent over-exposure, while supporting natural vitamin D production.
- 18 February 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (2) , 2465-2481
Open AccessVitamin D and Sun Exposure: A Community Survey in Australia
Sun exposure carries both harms and benefits. Exposing the skin to the sun is the main modifiable cause of skin cancers, which exert a considerable health and economic burden in Australia. The most well-established benefit of exposure to ultraviolet (UV) radiation is vitamin D production. Australia has the highest incidence of skin cancer in the world but, despite the high ambient UV radiation, approximately one quarter of the population is estimated to be vitamin D deficient. Balancing the risks and benefits is challenging and requires effective communication. We sought to provide a snapshot of public knowledge and attitudes regarding sun exposure and vitamin D and to examine the associations between these factors and sun protective behaviors. In 2020 we administered an online survey; 4824 participants with self-reported fair or medium skin color were included in this analysis. Only 25% and 34% of participants were able to identify the amount of time outdoors needed to maintain adequate vitamin D status in summer and winter, respectively and 25% were concerned that sunscreen use inhibits vitamin D synthesis. This lack of knowledge was associated with suboptimal sun protection practices. Public education is warranted to prevent over-exposure, while supporting natural vitamin D production.
- Open Access
- 1 August 2021
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 12 (6) , 1428-1439
Vitamin D supplementation and risk of falling: outcomes from the randomized, placebo‐controlled D‐Health Trial
Background: Falls cause considerable morbidity and mortality in older people. It is unclear how vitamin D supplementation affects falls risk, particularly when taken at high doses. We sought to determine whether monthly high‐dose vitamin D supplementation reduces risk and incidence of falls.Methods: We used data from the randomized, double‐blind, placebo‐controlled D‐Health Trial conducted in Australia. Between February 2014 and May 2015, 21 315 participants aged 60–84 years were randomized (1:1) to monthly doses of either 60 000 IU of colecalciferol or placebo for a maximum of 5 years. People who reported a history of osteomalacia, sarcoidosis, hyperparathyroidism, hypercalcaemia or kidney stones or who were taking >500 IU/day supplementary vitamin D were ineligible. Each year, we collected blood samples from ~450 randomly sampled participants from each trial arm and measured 25‐hydroxyvitamin D [25(OH)D]. Falls, a prespecified tertiary outcome, were ascertained using annual surveys and, for a subset of participants, 3‐month falls diaries. The primary outcome for this analysis was any fall in the month before completing an annual survey. As part of our process to maintain blinding, we used random samples of participants (surveys, n = 16 000; diaries, n = 2400), with equal numbers per group. Participants with no outcome data were excluded. Following an intention‐to‐treat approach, we analysed outcomes using logistic, ordinal and negative binomial regression. Registration: Australian New Zealand Clinical Trials Registry (ACTRN12613000743763); registered 4 July 2013.Results: Mean treatment duration was 4.3 years (standard deviation [SD] = 1.4 years). Mean serum 25(OH)D concentrations during the trial were 114.8 (SD 30.3) nmol/L and 77.5 (SD 25.2) nmol/L in the vitamin D and placebo groups, respectively. Survey and diary analytic sets included 15 416 and 2200 participants, respectively; approximately half were randomized to vitamin D (surveys: 50.1%; diaries: 50.4%). Vitamin D had no effect on falling in the past month (odds ratio [OR] 1.02, 95% confidence interval [CI] 0.95–1.10). There was an interaction with body mass index (BMI) (P‐interaction = 0.001); vitamin D increased risk in participants with BMI < 25 kg/m2 (OR 1.25, 95% CI 1.09–1.43), but there was no effect in those with BMI ≥ 25 kg/m2 (OR 0.95, 95% CI 0.87–1.04). Analyses of diary data were consistent with these findings. The incidence of hypercalcaemia and kidney stones did not differ between groups.Conclusions: Monthly high‐dose vitamin D supplementation did not reduce risk of falling. A possible increased risk of falling with vitamin D supplementation in people with normal BMI warrants further investigation.
- 1 August 2021
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 12 (6) , 1428-1439
Open AccessVitamin D supplementation and risk of falling: outcomes from the randomized, placebo‐controlled D‐Health Trial
Background: Falls cause considerable morbidity and mortality in older people. It is unclear how vitamin D supplementation affects falls risk, particularly when taken at high doses. We sought to determine whether monthly high‐dose vitamin D supplementation reduces risk and incidence of falls.Methods: We used data from the randomized, double‐blind, placebo‐controlled D‐Health Trial conducted in Australia. Between February 2014 and May 2015, 21 315 participants aged 60–84 years were randomized (1:1) to monthly doses of either 60 000 IU of colecalciferol or placebo for a maximum of 5 years. People who reported a history of osteomalacia, sarcoidosis, hyperparathyroidism, hypercalcaemia or kidney stones or who were taking >500 IU/day supplementary vitamin D were ineligible. Each year, we collected blood samples from ~450 randomly sampled participants from each trial arm and measured 25‐hydroxyvitamin D [25(OH)D]. Falls, a prespecified tertiary outcome, were ascertained using annual surveys and, for a subset of participants, 3‐month falls diaries. The primary outcome for this analysis was any fall in the month before completing an annual survey. As part of our process to maintain blinding, we used random samples of participants (surveys, n = 16 000; diaries, n = 2400), with equal numbers per group. Participants with no outcome data were excluded. Following an intention‐to‐treat approach, we analysed outcomes using logistic, ordinal and negative binomial regression. Registration: Australian New Zealand Clinical Trials Registry (ACTRN12613000743763); registered 4 July 2013.Results: Mean treatment duration was 4.3 years (standard deviation [SD] = 1.4 years). Mean serum 25(OH)D concentrations during the trial were 114.8 (SD 30.3) nmol/L and 77.5 (SD 25.2) nmol/L in the vitamin D and placebo groups, respectively. Survey and diary analytic sets included 15 416 and 2200 participants, respectively; approximately half were randomized to vitamin D (surveys: 50.1%; diaries: 50.4%). Vitamin D had no effect on falling in the past month (odds ratio [OR] 1.02, 95% confidence interval [CI] 0.95–1.10). There was an interaction with body mass index (BMI) (P‐interaction = 0.001); vitamin D increased risk in participants with BMI < 25 kg/m2 (OR 1.25, 95% CI 1.09–1.43), but there was no effect in those with BMI ≥ 25 kg/m2 (OR 0.95, 95% CI 0.87–1.04). Analyses of diary data were consistent with these findings. The incidence of hypercalcaemia and kidney stones did not differ between groups.Conclusions: Monthly high‐dose vitamin D supplementation did not reduce risk of falling. A possible increased risk of falling with vitamin D supplementation in people with normal BMI warrants further investigation.
- 1 May 2021
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 104, 106347
Predicting deseasonalised serum 25 hydroxy vitamin D concentrations in the D-Health Trial: An analysis using boosted regression trees
- 1 May 2021
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 104, 106347
Predicting deseasonalised serum 25 hydroxy vitamin D concentrations in the D-Health Trial: An analysis using boosted regression trees
- 1 October 2020
- Published by Elsevier in Pancreatology
- Vol. 20 (7) , 1458-1464
Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis
- 1 October 2020
- Published by Elsevier in Pancreatology
- Vol. 20 (7) , 1458-1464
Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis